📑Cjepivo protiv humanog papiloma virusa, rekombinantno, adsorbirano, za 2017. godinu
Procurement process summary
This process is to purchase Cjepivo protiv humanog papiloma virusa, rekombinantno, adsorbirano, za 2017. godinu.
This contract was awarded by 🇭🇷 Hrvatski zavod za javno zdravstvo for an amount of HRK 6,650,000 to 1 supplier. It was published on 2017-03-17 through open
Transparency in this process is reflected in the detailed publication of all aspects of the contract and its results.
Buying entity🇭🇷 Hrvatski zavod za javno zdravstvo Buying unitnot reported Publication date2017-03-17 Contest statusnot reported DescriptionCjepivo protiv humanog papilomavirusa, rekombinantno, adsorbirano, za 2017. godinu.Awards
This award was granted to Merck Sharp & Dohme B.V. by Hrvatski zavod za javno zdravstvo for an amount of HRK 6,650,000. The procurement process was conducted through open for the category of goods. This is award number 1.
| Supplier | Amount | Award number |
|---|---|---|
| 🇳🇱 Merck Sharp & Dohme B.V. | HRK 6,650,000 | 1 |
Market context and opportunities
The execution of this contract allows the entity Hrvatski zavod za javno zdravstvo to fulfill its public service objectives efficiently.
The open purchase modality ensures that the process is transparent and compliant with regulations.
Transparency in this process is reflected in the detailed publication of all aspects of the contract and its results.
This transparency in public procurement promotes fair competition, prevents corruption, and ensures that public resources are used efficiently for the benefit of citizens.
Additional data
Contract NumberHR_ocds-70d2nz-78dce8f5-e35b-4e03-bbe8-a1d12791c5f6-award-1Publication date2017-03-17Contract datenot reportedAward datenot reportedCategoriesgoodsPurchase modalityopenMethod detailspt_openStatusnot reportedData sources
Sociedad.info publishes data from official sources, in compliance with public information access laws. Public access to this data is a civic right that helps hold government accountable. This data, including names and identifiers, is already public in the official source. Read our privacy policy.
